Although Amicus Therapeutics is located in New Jersey, the biopharmaceutical company is making huge strides around the globe. The company’s focus is on treating a wide range of devastating rare and orphan diseases. These diseases include Pompe Disease, Fabry Disease, and other Lysosomal Storage Disorders(LCDs) (Indeed). The company has an ongoing product pipeline that addresses the needs of those suffering from these diseases.
Amicus Therapeutics scientists dedicate their time and research to finding treatment for rare and orphan diseases through innovation and technology. These groundbreaking findings allow for patients to benefit from the enhanced treatments that the research uncovers.
The company has goals for those working within the company and for those that the company hopes to wish through its work. Amicus Therapeutics believes in the continuous growth of ideas to remain at the forefront of learning more about rare diseases. The company takes smart risks to ensure that they are doing everything possible on behalf of those suffering from these rare diseases. The company supports the patients and the families of those affected by giving them hope and education. The company believes in being honest and ethical to provide long lasting partnerships with other companies. Producing medicines that are reasonably priced and easily obtainable is important to Amicus Therapeutics.
Amicus Therapeutics has teamed with patient organizations, families, and healthcare providers to ensure that the company is doing all that is possible to positively advocate for those in need. Because the diseases are so rare that Amicus Therapeutics works to treat, it is essential that the company reaches out to all in need of help. Today, the company is continuing its work, by developing treatments and introducing new ideas on how to help those in need of the research and medicines that have been discovered. The company promises also to continue to educate about these rare and orphan diseases so that others can help in the fight to advocate on behalf of those in need.
More about Amicus Therapeutics https://twitter.com/amicusrx1?lang=en
While many investors like to pride themselves on success through believing what they got right, some actually look at where they could be wrong and build on that. Such an investor is Paul Mampilly, the author of “Profits Unlimited” at Banyan Hill Publishing.
Mampilly told Ideamensch when asked about his work that he sometimes looks at where he could be wrong in order to figure out where to go right the next time. Mampilly said he’s focused his investments on popular millennial apps and also looks at things related to the “internet of all things.” Mampilly is also releasing a new newsletter titled “True Momentum.”
Paul Mampilly was born in India and moved to the US in 1991 to become an investment banker. He had to work hard to get through college at Fordham University, but by 1996 he had landed a job at the prominent Deutsche Bank. From there he became an investment expert and advisor for clients at ING, Bankers Trust, Royal Bank of Scotland and Sears. He left banking and joined a growing hedge fund known as Kinetics International Fund. He made headlines in Barron’s magazine when he grew the firm’s assets under management to $25 billion and made investments that yielded as much as 26% in annual returns.
Paul Mampilly drew the attention of top level Wall Street bankers who formed the Templeton Foundation and invited him to join their 2008 investment competition. He took a $50 million fund and turned it into an $88 million fund in just one year even though the recession hit many other investors hard that year. A few years after winning this prestigious competition, Mampilly decided to retire though only in the technical sense. He continued investing on his own and in the coming years saw big profits made in stocks such as Facebook, CEMEX, Sarepta Therapeutics and Netflix. The idea behind his newsletters is to give unaccredited investors the same opportunities that Wall Street bankers have had and to manage their portfolios without broker fees and interference. “Profits Unlimited” started in 2016 and in only a few months gained 60,000 followers.
Read more: The Must Have Tech of 2017
The Capital Group is one of the leading hedge funds in the country. For the past 20 years, it has been led by Tim Armour, who has continued to oversee capital raising and portfolio management strategies. Tim Armour was recently interviewed on CNBC and he had an interesting take on a recent bet made between Warren Buffet and a few different mutual funds.
About one year ago, Buffet bet several top mutual funds that he could earn a better return on investment by simply investing in a low-cost index fund. Ultimately, Buffet was proven successful in his bet, which has made many people reconsider their investment strategies.
Read more on CityWireSelector.com.
While Buffet clearly won the bet, Tim Armour has stated that he doesn’t think that index funds are necessarily the best long-term investment option. Armour pointed out that during the bet period, the overall stock market went up a lot. While hedge funds can do well during these periods, their true value comes when they have to perform during a bearish market. During a period of economic downturn, hedge funds have the ability to hedge risks, which can limit losses. On the other hand, those that invest in index funds will not have any protection.
Armour further pointed out that one year is not enough of a trend to depend on. He pointed out that over the past 20 years, the Capital Group has earned a return of 1.5% higher on average than the overall stock market returns even after factoring in fund fees.
Find more about Timothy Armour: http://relationshipscience.com/timothy-d-armour-p3247776